No single result settles the question. A clinician reads the antibody pattern alongside your symptoms, your history of dust and soil exposure, your chest imaging and the rest of your blood work before deciding what happens next.
Most of the time it looks for your immune response to the fungus rather than the fungus itself. Valley fever, known clinically as coccidioidomycosis, follows inhalation of airborne spores from Coccidioides species that live in dry soil, and the lungs are the usual first site of infection 1. Once the organism is inhaled, the immune system begins producing antibodies against it, IgM first and IgG afterwards. Antibody tests read that response and translate it into a result a clinician can act on.
Three antibody methods are in routine use, and they answer slightly different questions. Enzyme immunoassay (EIA) is a rapid method many laboratories use as a first pass. Immunodiffusion looks for precipitating antibodies and is often used to confirm what EIA reports. Complement fixation produces a number, a titre, which can be followed over time. Serological testing of this kind is the backbone of diagnosis in everyday practice 2.
Direct testing takes another route entirely. Sputum or tissue can be cultured, or examined under the microscope for spherules, the distinctive tissue form of the organism, which is a definitive finding when it is seen 3. Antigen testing looks for fungal material in body fluids rather than for antibodies and is generally reserved for severe or widespread infection.
Research suggests that, in immunocompetent people, most of these infections are self limited and settle without lasting problems 5.
Testing is usually prompted by a chest illness that drags on longer than expected after possible exposure to dry, dusty soil. The common picture includes cough, fever, chest discomfort, night sweats, headache, aching joints and fatigue that is heavier than the cough alone would explain 6.
Skin changes are a recognised part of the early illness and often bring people in. Tender red nodules on the shins, called erythema nodosum, and the target shaped lesions of erythema multiforme can appear as the immune system responds to primary infection 7. These are immune reactions rather than infection in the skin itself, which is why they can appear while the main trouble is still in the lungs.
A second common trigger for testing is a chest infection that behaves oddly. When a cough, fever and fatigue persist for weeks, when fatigue lingers after the fever has gone, or when a chest X-ray shows something that does not match the clinical course, a clinician may add antibody testing to the work up 8.
The fuller picture, including how the illness tends to evolve week by week and which features matter most, is covered in the guide to valley fever symptoms. For testing purposes, the practical rule is simple. Symptoms plus a plausible exposure history is what moves a clinician from watching to ordering.
They differ in speed, in what they confirm and in whether they produce a number. Most laboratories use them in sequence rather than choosing between them, and the panel a clinician orders often includes more than one.
| Test | What it measures | What it is mainly used for | Practical notes |
|---|---|---|---|
| Enzyme immunoassay (EIA) | IgM and IgG antibodies | Rapid first line screening | Sensitive and quick; a reactive result is commonly confirmed by another method |
| Immunodiffusion (ID) | Precipitating IgM and IgG antibodies | Confirming a reactive EIA | Qualitative, reported as present or absent |
| Complement fixation (CF) | IgG antibody level as a titre | Gauging extent of infection and following it over time | Produces a number that can be repeated and compared |
| Culture and microscopy | The organism itself | Definitive identification | Needs sputum, fluid or tissue, not blood |
| Antigen testing | Fungal antigen in body fluids | Severe or widespread infection, or blunted immune response | May be negative in mild illness |
Serology is used this way because no single method covers every situation. EIA finds early responders quickly, immunodiffusion reduces the chance that a reactive screen stands alone, and complement fixation adds the quantitative element that follow up depends on 2. Laboratories vary in which assays they run in house and which they send to a reference laboratory, so the exact panel name on your order form may differ from the names above while measuring the same things.
Because antibodies take time to build, and the test is reading antibodies rather than the fungus. Someone tested in the first days or weeks of symptoms may have a genuinely negative antibody result while infection is already under way. Studies indicate that serological testing can be negative early in the course of pulmonary coccidioidomycosis, which is why a single negative result does not close the question 8.
This is the single most important thing to understand about a valley fever test. A negative result in week one means the antibody response has not yet reached a detectable level, not that the illness has been ruled out. When suspicion remains, clinicians commonly repeat the test later, and the timing of that repeat is a clinical judgement rather than a fixed calendar rule.
Antibody responses can also be muted for reasons that have nothing to do with timing. In people with weakened immune systems, the antibody response may be weaker or slower, and direct testing of sputum or tissue, or antigen testing, carries more weight in that setting 3.
The practical consequence is worth stating plainly. If you were tested very early and told the result was negative, and your cough, fever or fatigue has not improved, that is a reason to go back to the clinician who ordered it rather than a reason to assume the question is settled.
It adds a number that can be compared with itself over time. Enzyme immunoassay and immunodiffusion largely answer yes or no. Complement fixation reports how much antibody is present, expressed as a titre, and that figure can be repeated weeks or months later to see which direction things are moving.
A higher complement fixation titre is associated with more extensive infection, including spread beyond the lungs, which is why clinicians pay attention to the size of the number and not only its presence 6. A falling titre over serial samples generally points the other way. Because laboratories differ in technique, titres are most meaningful when the same laboratory runs the repeat samples, and your clinician will usually try to keep follow up testing in one place.
Complement fixation also has a role outside blood. When central nervous system involvement is suspected, testing of cerebrospinal fluid obtained by lumbar puncture can be part of the work up 4. That is a hospital level decision, not a routine outpatient test, and it is made by the clinician managing the case.
For most people with a straightforward chest illness, the titre is simply a tracking tool. It gives the clinician a way to tell whether the immune picture is settling, holding steady or intensifying, which is information that symptoms alone can be slow to reveal.
Antibody testing uses an ordinary venous blood draw from the arm, the same as any other blood panel. No fasting is usually required for the antibody tests themselves, although other tests drawn at the same visit may carry their own instructions, so it is worth confirming with the laboratory before you go.
What happens after the draw depends on the laboratory. Some run enzyme immunoassay on site and send immunodiffusion and complement fixation to a reference laboratory, which lengthens the wait for the full panel. Turnaround varies by laboratory and by method, so ask the ordering clinician what to expect for your specific panel rather than planning around a fixed number of days.
If a sputum sample is being sent as well, it helps for the laboratory to know that coccidioidomycosis is being considered, because the organism grows as a mould in culture and requires appropriate handling in the laboratory. Your clinician handles that communication, but it explains why the request form sometimes carries a note about suspected fungal infection.
Results usually return as a set. A typical report lists whether IgM and IgG were detected by each method and, where complement fixation was run, the titre. None of those lines is a diagnosis on its own. They are inputs that a clinician combines with your exposure history, your examination and your imaging.
A chest X-ray is often the first imaging test ordered, and it tells the clinician what the lungs look like while the blood tells them what the immune system is doing. Reported findings in pulmonary coccidioidomycosis include patchy infiltrates, single or multiple nodules, cavities, enlarged lymph nodes at the lung roots and fluid in the pleural space 8.
None of those appearances is unique to this infection, which is the central limitation. An infiltrate on a chest X-ray looks much the same whether the cause is bacterial or fungal, and a nodule found incidentally can raise questions that only further testing can answer. That is why imaging and antibody testing are read together rather than separately.
A normal chest X-ray does not rule the illness out, particularly early on or in someone with mild symptoms. Equally, a visible abnormality does not confirm the diagnosis without supporting laboratory results. When a clinician needs more anatomical detail, a CT scan of the chest may be arranged, and any scan preparations are explained by the imaging service at the time.
The practical takeaway is that imaging answers a different question from the blood test. The X-ray describes what is happening in the lung tissue. The antibody test describes what the immune system has recognised. The diagnosis sits in the overlap.
They can show the organism itself, which blood antibody testing never does. Culture of sputum, respiratory fluid or tissue can grow Coccidioides, and microscopic examination can reveal spherules containing endospores, the form the organism takes in human tissue 3. Finding either one is as close to certainty as the laboratory gets.
Direct testing matters most in three situations. The first is when antibody results are negative or equivocal but suspicion stays high. The second is when the immune response may be blunted, so serology is a less reliable narrator. The third is when a lesion needs explaining on its own terms, for example a lung nodule or a skin lesion being sampled for another reason. Skin lesions sampled during evaluation can show the organism on histopathology, which is one way the diagnosis is first made.
Getting a usable sample is the practical obstacle. Many people with this illness produce little sputum, so obtaining material may require bronchoscopy or a biopsy, both of which are procedures a clinician recommends only when the information will change what happens next.
Antigen testing sits between the two approaches. It looks for fungal material rather than growing the organism and is generally used when infection is severe or widespread.
A positive antibody result means your immune system has encountered Coccidioides. It does not, by itself, prove that infection is active right now, and it is never a diagnosis made by the laboratory.
The interpretation runs in three steps. The observation is the pattern on the report, for example IgM detected by EIA, or IgG confirmed by immunodiffusion with a measurable complement fixation titre. The possible meaning depends on timing, because IgM tends to reflect a recent response while IgG appears later and can persist for a long period after the illness has settled, so antibodies found in someone with no symptoms may reflect a past encounter rather than a current one 2. The next step is a conversation with the clinician who ordered the test, who reads the result against your symptoms, your exposure and your imaging.
A reactive screen followed by a negative confirmatory test is a genuinely different situation from two concordant positives, and the clinician weighs them differently.
If your result is positive, the useful question to ask is not whether the number is good or bad. It is what the pattern suggests about timing, whether a repeat titre is planned and what would change the plan. Treatment decisions belong to a licensed provider who has reviewed the whole case.
A negative result with ongoing symptoms is a reason to keep going, not to stop. The first consideration is timing, because an antibody test taken early can be negative while the response is still developing 8, and a repeat sample later may read differently.
The second consideration is the method. If only a rapid screen was run, a clinician may add immunodiffusion and complement fixation, or move towards direct testing of sputum or tissue if a sample can be obtained 3.
The third consideration is whether something else explains the illness. A persistent cough with fever has a long list of possible causes, and the overlap with bacterial chest infection is wide enough that the two are regularly confused in the first week or two 1. Comparing your own course against the pattern described in the guide to pneumonia symptoms can help you describe the illness more precisely when you go back.
What matters most is not letting a single negative result end the conversation while you still feel unwell. Document when symptoms started, what has changed and what has not, and bring that timeline to the follow up appointment. Timing detail is exactly what the clinician needs in order to judge whether a repeat test is likely to be informative.
Eosinophils are a white blood cell type reported on a standard complete blood count, and a raised eosinophil count can accompany coccidioidomycosis, which is why the differential count is often read alongside antibody results. Compare your result with the range printed on your lab report. FitScript's optimal range is 1 to 4 %. FitScript's optimal ranges are optimization targets, not diagnostic cut-offs, and ranges vary by lab, age and sex.
A raised percentage is not specific to any one cause, so it supports a clinical picture rather than creating one. For what this marker measures, how it is tested and how to read your own number, see Eosinophils.
A complete blood count and general inflammatory markers are the usual companions, because they describe how the body is responding while the antibody panel identifies what it is responding to. A full blood count with differential shows the white cell pattern. Inflammatory markers such as C-reactive protein and erythrocyte sedimentation rate, reported in whatever units your laboratory uses, give a rough sense of how much inflammation is present. Neither is specific, and neither can identify an organism.
A metabolic panel is often added, covering kidney and liver markers. Compare your result with the range printed on your lab report. Baseline values matter because they describe your starting point before any clinical decision is made, and because some medicines can change blood counts and chemistry results. Ask your prescriber about anything you already take before drawing conclusions from a shifted value.
Broader panels are a different exercise from diagnostic testing. FitScript tests 150+ biomarkers per year and Atlas, FitScript's AI health advisor, interprets those results in the context of a member's wider pattern. That kind of longitudinal picture is useful for understanding trends over time, while an acute respiratory illness still needs targeted testing ordered and read by the clinician managing it.
People whose immune defences are reduced, and people with signs that infection has moved beyond the lungs, are followed more closely. Infection that spreads can involve skin, bone, joints and the central nervous system, and these presentations are recognised across the clinical literature 6.
Immune status is the clearest factor. In people with weakened immune systems, both the course of infection and the reliability of antibody testing can differ, which changes how often results are repeated and how much weight direct testing carries 3.
Skin involvement deserves a separate mention because it is visible. Nodules, plaques or ulcers that appear during or after a chest illness can represent infection in the skin itself rather than a reactive rash, and distinguishing the two often requires sampling the lesion. Reactive rashes such as erythema nodosum behave differently from lesions containing the organism, and the distinction changes the clinical path.
Extent of lung involvement also matters. Widespread changes on imaging, cavities or lasting lymph node enlargement tend to earn repeat imaging and repeat titres. None of this is something to self assess from a report. It is the reason follow up appointments are scheduled rather than left open.
Mainly by testing, because the symptoms overlap heavily. A cough, fever, fatigue and an infiltrate on a chest X-ray look much the same from the outside whether the cause is bacterial or fungal.
A few features shift suspicion. An illness that lasts longer than a routine chest infection, profound fatigue out of proportion to the cough, night sweats, joint aches or a rash such as erythema nodosum can all point a clinician towards fungal testing rather than away from it 6. A relevant exposure history, including time spent around disturbed dry soil or dust, adds weight.
None of those features is reliable enough to decide anything alone, which is the whole reason the antibody panel exists. The honest summary is that the clinical picture raises the question and the laboratory answers it, sometimes only after a repeat sample.
This also explains why a chest infection that does not follow the expected arc is worth reporting back. The information a clinician needs in order to reconsider the diagnosis is the course over time, and that is something only the person living through it can supply accurately.
Any respiratory illness that lasts beyond a couple of weeks, or that improves and then worsens again, is worth a conversation, particularly after exposure to dry, dusty conditions. The same applies to a positive antibody result, an abnormal chest X-ray or a negative result that does not match how you feel.
Some features deserve prompt attention rather than a routine appointment. Breathlessness at rest, coughing up blood, a severe or persistent headache, new weakness or confusion, new skin nodules or ulcers, swollen painful joints, or weight loss and drenching night sweats are all reasons to contact a clinician promptly, especially in people with weakened immune systems. None of that means the worst has happened. It means the picture needs a trained assessment sooner rather than later.
Bring specifics to the appointment. When symptoms started, what has changed, where you have been, what tests have already been run and on which dates. Antibody results gain most of their meaning from timing, so a clear timeline is genuinely diagnostic information.
This article is educational and is not medical advice. Discuss your results, your symptoms and any treatment with a clinician or licensed provider who can review your full history.
It depends on the laboratory and on which methods were ordered. Rapid antibody screens are often run on site, while immunodiffusion and complement fixation may be sent to a reference laboratory, which lengthens the wait. Ask the clinician who ordered the panel what to expect for your specific tests rather than planning around a fixed number of days.
Fasting is not usually required for the antibody tests themselves, which use an ordinary blood draw from the arm. Other tests drawn at the same visit may have their own preparation instructions. Confirm with the laboratory or the ordering clinician before your appointment.
Yes. Antibodies take time to build, so a sample taken in the first days or weeks of symptoms can read negative while infection is already under way. A repeat sample later may read differently. If symptoms continue, go back to the clinician who ordered the test rather than assuming the question is closed.
No. A chest X-ray shows what the lungs look like, and the appearances overlap with other chest infections. A normal X-ray also does not rule the illness out. Imaging and antibody testing are read together by a clinician, not separately.
It means your immune system has encountered the fungus at some point. It does not by itself confirm that infection is active now, because some antibodies persist long after an illness has settled. The clinician who ordered the test interprets it alongside your symptoms, exposure history and imaging.
Not directly. A routine panel may show general clues such as a raised eosinophil percentage or markers of inflammation, but none of those identifies an organism. A specific antibody test has to be ordered for that question.
That is a clinical judgement rather than a fixed schedule. Complement fixation titres are often repeated so the clinician can compare the number against earlier samples, ideally at the same laboratory. Your clinician decides the timing based on your symptoms and your first results.
A clinician usually orders it as part of a work up for a persistent chest illness, and the same clinician interprets the report in context. Availability of specific antibody methods varies between laboratories. Any decision about what happens after the result belongs to a licensed provider who has reviewed your full history.